114 related articles for article (PubMed ID: 34404130)
21. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
22. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3).
Fossati M; Buzzonetti A; Monego G; Catzola V; Scambia G; Fattorossi A; Battaglia A
Gynecol Oncol; 2015 Aug; 138(2):343-51. PubMed ID: 26049121
[TBL] [Abstract][Full Text] [Related]
23. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features.
D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Fusilli S; Zendoli F; Carotenuto M
Haematologica; 1998 Mar; 83(3):197-203. PubMed ID: 9573672
[TBL] [Abstract][Full Text] [Related]
24. CD56
Wang H; Zeng Y; Zhang M; Ma H; Xu B; Jiang H; Wang J; Li G
Hum Immunol; 2019 Oct; 80(10):871-877. PubMed ID: 31326139
[TBL] [Abstract][Full Text] [Related]
25. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
26. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
27. Identification of Tissue-Resident Natural Killer and T Lymphocytes with Anti-Tumor Properties in Ascites of Ovarian Cancer Patients.
Bernson E; Huhn O; Karlsson V; Hawkes D; Lycke M; Cazzetta V; Mikulak J; Hall J; Piskorz AM; Portuesi R; Vitobello D; Fiamengo B; Siesto G; Horowitz A; Ghadially H; Mavilio D; Brenton JD; Sundfeldt K; Colucci F
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444472
[TBL] [Abstract][Full Text] [Related]
28. Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida.
Valiathan R; Deeb K; Diamante M; Ashman M; Sachdeva N; Asthana D
Immunobiology; 2014 Jul; 219(7):487-96. PubMed ID: 24661720
[TBL] [Abstract][Full Text] [Related]
29. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.
da Silva RF; Yoshida A; Cardozo DM; Jales RM; Paust S; Derchain S; Guimarães F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513532
[TBL] [Abstract][Full Text] [Related]
30. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
[TBL] [Abstract][Full Text] [Related]
31. Expanded CD56
Poznanski SM; Nham T; Chew MV; Lee AJ; Hammill JA; Fan IY; Butcher M; Bramson JL; Lee DA; Hirte HW; Ashkar AA
Cancer Immunol Res; 2018 Oct; 6(10):1174-1185. PubMed ID: 30018043
[TBL] [Abstract][Full Text] [Related]
32. Fc gamma RIII activation is different in CD16+ cytotoxic T lymphocytes and natural killer cells.
Uciechowski P; Gessner JE; Schindler R; Schmidt RE
Eur J Immunol; 1992 Jun; 22(6):1635-8. PubMed ID: 1376268
[TBL] [Abstract][Full Text] [Related]
33. Natural Killer Group 2A Expressed on Both Peripheral CD3
Yi RT; Niu YH; Liu HL; Zhang TY; Yang YC; Zhang Y; Yin DL; Chen TY; Zhao YR
J Interferon Cytokine Res; 2016 Dec; 36(12):689-697. PubMed ID: 27828717
[TBL] [Abstract][Full Text] [Related]
34. Foxp3(high) and Foxp3(low) Treg cells differentially correlate with T helper 1 and natural killer cells in peripheral blood.
Lee SK; Kim JY; Jang BW; Hur SE; Na BJ; Lee M; Fukui A; Gilman-Sachs A; Kwak-Kim J
Hum Immunol; 2011 Aug; 72(8):621-6. PubMed ID: 21600259
[TBL] [Abstract][Full Text] [Related]
35. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
Belisle JA; Gubbels JA; Raphael CA; Migneault M; Rancourt C; Connor JP; Patankar MS
Immunology; 2007 Nov; 122(3):418-29. PubMed ID: 17617155
[TBL] [Abstract][Full Text] [Related]
36. Immunophenotype of peripheral T lymphocytes, NK cells and expression of CD69 activation marker in patients with recurrent spontaneous abortions, during the mid-luteal phase.
Prado-Drayer A; Teppa J; Sánchez P; Camejo MI
Am J Reprod Immunol; 2008 Jul; 60(1):66-74. PubMed ID: 18593439
[TBL] [Abstract][Full Text] [Related]
37. Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites.
Hrvat A; Schmidt M; Wagner B; Zwanziger D; Kimmig R; Volbracht L; Brandau S; Mallmann-Gottschalk N
J Exp Clin Cancer Res; 2023 Sep; 42(1):235. PubMed ID: 37684704
[TBL] [Abstract][Full Text] [Related]
38. Normal Values of T, B and NK Lymphocyte Subpopulations in Peripheral Blood of Healthy Cuban Adults.
Kokuina E; Breff-Fonseca MC; Villegas-Valverde CA; Mora-Díaz I
MEDICC Rev; 2019; 21(2-3):16-21. PubMed ID: 31373580
[TBL] [Abstract][Full Text] [Related]
39. Early Cytomegalovirus Reactivation and Expansion of CD56
Jang JE; Hwang DY; Chung H; Kim SJ; Eom JI; Jeung HK; Song J; Kim JS; Cheong JW; Min YH
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2070-2078. PubMed ID: 31212079
[TBL] [Abstract][Full Text] [Related]
40. CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation.
Morandi F; Horenstein AL; Chillemi A; Quarona V; Chiesa S; Imperatori A; Zanellato S; Mortara L; Gattorno M; Pistoia V; Malavasi F
J Immunol; 2015 Aug; 195(3):965-72. PubMed ID: 26091716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]